425 related articles for article (PubMed ID: 32166538)
1. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
Adv Ther; 2020 Apr; 37(4):1620-1631. PubMed ID: 32166538
[TBL] [Abstract][Full Text] [Related]
2. Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial.
Asrani S; Robin AL; Serle JB; Lewis RA; Usner DW; Kopczynski CC; Heah T;
Am J Ophthalmol; 2019 Nov; 207():248-257. PubMed ID: 31229466
[TBL] [Abstract][Full Text] [Related]
3. Once-Daily Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure in the Randomized Phase 3 MERCURY-2 Study.
Walters TR; Ahmed IIK; Lewis RA; Usner DW; Lopez J; Kopczynski CC; Heah T;
Ophthalmol Glaucoma; 2019; 2(5):280-289. PubMed ID: 32672669
[TBL] [Abstract][Full Text] [Related]
4. One Year of Netarsudil and Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Phase 3, Randomized MERCURY-1 Study.
Brubaker JW; Teymoorian S; Lewis RA; Usner D; McKee HJ; Ramirez N; Kopczynski CC; Heah T
Ophthalmol Glaucoma; 2020; 3(5):327-338. PubMed ID: 32768361
[TBL] [Abstract][Full Text] [Related]
5. MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.
Stalmans I; Lim KS; Oddone F; Fichtl M; Belda JI; Hommer A; Laganovska G; Schweitzer C; Voykov B; Zarnowski T; Holló G
Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):179-190. PubMed ID: 37615697
[TBL] [Abstract][Full Text] [Related]
6. Netarsudil/latanoprost fixed-dose combination for the treatment of open-angle glaucoma or ocular hypertension.
Radell JE; Serle JB
Drugs Today (Barc); 2019 Sep; 55(9):563-574. PubMed ID: 31584573
[TBL] [Abstract][Full Text] [Related]
7. Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.
Clement Freiberg J; von Spreckelsen A; Kolko M; Azuara-Blanco A; Virgili G
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD013817. PubMed ID: 35686679
[TBL] [Abstract][Full Text] [Related]
8. Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension.
Singh IP; Fechtner RD; Myers JS; Kim T; Usner DW; McKee H; Sheng H; Lewis RA; Heah T; Kopczynski CC
J Glaucoma; 2020 Oct; 29(10):878-884. PubMed ID: 32826769
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of topically administered netarsudil-latanoprost fixed dose combination (FDC; Rocklatan™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).
Leary KA; Steibel JP; Harman CD; Anderson AL; Komáromy AM
Vet Ophthalmol; 2021 Nov; 24(6):610-619. PubMed ID: 34085750
[TBL] [Abstract][Full Text] [Related]
10. Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2.
Wisely CE; Sheng H; Heah T; Kim T
Adv Ther; 2020 Mar; 37(3):1114-1123. PubMed ID: 31981106
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis.
Lee JW; Ahn HS; Chang J; Kang HY; Chang DJ; Suh JK; Lee H
Korean J Ophthalmol; 2022 Oct; 36(5):423-434. PubMed ID: 35989070
[TBL] [Abstract][Full Text] [Related]
12. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
Bacharach J; Dubiner HB; Levy B; Kopczynski CC; Novack GD;
Ophthalmology; 2015 Feb; 122(2):302-7. PubMed ID: 25270273
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.
Araie M; Sugiyama K; Aso K; Kanemoto K; Kothapalli K; Kopczynski C; Senchyna M; Hollander DA
Adv Ther; 2021 Apr; 38(4):1757-1775. PubMed ID: 33629227
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting.
Zaman F; Gieser SC; Schwartz GF; Swan C; Williams JM
Curr Med Res Opin; 2021 Jun; 37(6):1011-1020. PubMed ID: 33733980
[TBL] [Abstract][Full Text] [Related]
15. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.
Lewis RA; Levy B; Ramirez N; Kopczynski CC; Usner DW; Novack GD;
Br J Ophthalmol; 2016 Mar; 100(3):339-44. PubMed ID: 26209587
[TBL] [Abstract][Full Text] [Related]
16. Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study.
Sit AJ; Gupta D; Kazemi A; McKee H; Challa P; Liu KC; Lopez J; Kopczynski C; Heah T
Am J Ophthalmol; 2021 Jun; 226():262-269. PubMed ID: 33524367
[TBL] [Abstract][Full Text] [Related]
17. Netarsudil and latanoprost ophthalmic solution for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension.
Aref AA; Geyman LS; Zakieh AR; Alotaibi HM
Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1073-1079. PubMed ID: 31842637
[No Abstract] [Full Text] [Related]
18. Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).
Kahook MY; Serle JB; Mah FS; Kim T; Raizman MB; Heah T; Ramirez-Davis N; Kopczynski CC; Usner DW; Novack GD;
Am J Ophthalmol; 2019 Apr; 200():130-137. PubMed ID: 30653957
[TBL] [Abstract][Full Text] [Related]
19. Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension.
Kopczynski CC; Heah T
Drugs Today (Barc); 2018 Aug; 54(8):467-478. PubMed ID: 30209441
[TBL] [Abstract][Full Text] [Related]
20. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
